Thus, based on these assumptions, in this study we investigated the ability of GSK343, a selective EZH2 inhibitor, to modulate the Wnt/β-catenin signaling pathway in oral cancer using an in vitro and in vivo model. Here, EZH2 is linked to lip and oral cavity carcinoma.